Michael Exton - Lexicon Pharmaceuticals CEO Director
| LXRX Stock | USD 0.34 0.02 5.56% |
CEO
Michael Exton is CEO Director of Lexicon Pharmaceuticals
| Age | 55 |
| Phone | 281 863 3000 |
| Web | https://www.lexpharma.com |
Michael Exton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Exton against Lexicon Pharmaceuticals stock is an integral part of due diligence when investing in Lexicon Pharmaceuticals. Michael Exton insider activity provides valuable insight into whether Lexicon Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Lexicon Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lexicon Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Exton over a month ago Acquisition by Michael Exton of 1509790 shares of Lexicon Pharmaceuticals subject to Rule 16b-3 |
Lexicon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4377) % which means that it has lost $0.4377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6766) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceuticals' management efficiency ratios could be used to measure how well Lexicon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | CEO Age | ||
| Jeremy MBA | Day One Biopharmaceuticals | 54 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Michael Raab | Ardelyx | 60 | |
| Denise ScotsKnight | Mereo BioPharma Group | 66 | |
| Malte MD | Hookipa Pharma | 63 | |
| Paula Ragan | X4 Pharmaceuticals | 55 | |
| Eric MBA | Seres Therapeutics | 49 | |
| Richard Adcock | Immunitybio | 56 | |
Management Performance
| Return On Equity | -1.68 | ||||
| Return On Asset | -0.44 |
Lexicon Pharmaceuticals Leadership Team
Elected by the shareholders, the Lexicon Pharmaceuticals' board of directors comprises two types of representatives: Lexicon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexicon. The board's role is to monitor Lexicon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lexicon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexicon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth MD, Senior Assurance | ||
| Lonnel Coats, CEO and President and Director | ||
| Chas Schultz, Executive Advocacy | ||
| Robert MD, Consultant Director | ||
| Tom Garner, Senior Officer | ||
| Suma Gopinathan, Vice Development | ||
| Desiree Gendron, Vice Training | ||
| Jeffrey JD, President CFO | ||
| Mike Kelly, Investor Officer | ||
| Michael Exton, CEO Director | ||
| Thomas Garner, Senior Officer | ||
| Kristen Alexander, Vice Accounting | ||
| Dixon Terry, Vice Compliance | ||
| Carrie Siragusa, Vice Marketing | ||
| Alan Main, Executive VP of CMC and Supply Operations | ||
| Brian Crum, General VP | ||
| Brian Corrigan, Senior Assurance | ||
| Wendy McDermott, Senior Resources | ||
| Scott Coiante, Senior CFO | ||
| Lisa DeFrancesco, Senior Communications |
Lexicon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lexicon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.68 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (0.77) % | ||||
| Current Valuation | (326.5 K) | ||||
| Shares Outstanding | 361.49 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 84.10 % | ||||
| Number Of Shares Shorted | 44.74 M | ||||
| Price To Earning | 21.02 X | ||||
| Price To Book | 0.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.